SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): April 13, 2017
Argos Therapeutics, Inc.
(Exact Name of Registrant as Specified
(State or Other Jurisdiction
4233 Technology Drive
Durham, North Carolina 27704
|(Address of Principal Executive Offices)
Registrant’s telephone number,
including area code: (919) 287-6300
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☒
On April 13, 2017, Lee Allen, M.D., Chief
Medical Officer of Argos Therapeutics (the “Company”), voluntarily resigned from the Company effective as of that date.
There were no disagreements between Dr. Allen and the Company or any officer or director of the Company which led to Dr. Allen’s
resignation. Dr. Allen had served as Chief Medical Officer since January 2016.
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ARGOS THERAPEUTICS, INC.
By: /s/ Lori R. Harrelson
Name: Lori R. Harrelson
Title: Vice President of Finance
DATED: April 13, 2017